Back to directory
AI & ML · AI Drug Discovery

Edison ScientificLaunch orchestrated by The Launch Video Company (TLVC)

The AI Scientist for R&D Teams

Director and CEO at FutureHouse and Edison Scientific. Building an AI scientist. https://t.co/aNx8D1QmfN. https://t.co/rQYoPOwV8Q
21K followers
TLVC Rating

Incredible hook and animations! The launch was executed brilliantly, racking up over 3 million views in just a matter of hours.

Community Rating
★★★★★
No ratings yet
Your rating
Sign in to rate this launch.

About

Edison Scientific is launching Kosmos, an autonomous AI agent built for pharmaceutical R&D teams that runs the kind of literature review, data analysis, and hypothesis generation that normally consumes weeks of researcher time. Incyte and Edison Scientific have entered a strategic collaboration to integrate the Kosmos AI platform across Incyte's research and development operations , with work initially focused on target discovery, validation, and predictive models of therapeutic performance trained on translational and clinical data . The launch matters because it is the first time Kosmos is being deployed across an active pharma pipeline, giving Edison a live test of whether agentic systems can meaningfully shorten timelines in commercial drug development. The technical premise is a persistent world model that updates as the agent runs experiments and analyses, so each result reshapes the next set of questions Kosmos asks. Edison frames Kosmos as the most compute-intensive language agent released so far, designed to produce complex outputs that require multiple chained steps of reasoning . The company has previously claimed that a single Kosmos run can read 1,500 papers and write 42,000 lines of code, with users estimating it does roughly six months of work in a day , framing that Edison is now putting to the test inside Incyte's programs. Edison is led by CEO Sam Rodriques and co-founder Andrew White, and is the commercial spinout of FutureHouse, the AI scientist nonprofit backed by former Google CEO Eric Schmidt and co-founded by Rodriques, a former group leader at The Francis Crick Institute . For founders and operators watching the AI-for-science space, the Incyte deal is a useful signal of how a large pharma is willing to wire an outside agent into its discovery stack rather than build the equivalent internally.
Tags
SeedProduct launchExplainerB2B3M-5MGlobalUSVertical AIFounder-led
Comments (7)
Sign in to join the discussion.
Nadia Oboye14d ago

The tweet hook is doing a lot of heavy lifting. Going from 'golden age of biology' to 'partnering with Incyte' in three lines is the kind of pacing I expect from a movie trailer, not a launch post.

Kostya M.14d ago

hot take: 'compress months of drug development' is the kind of claim that needs a footnote the size of a phonebook. what does Kosmos actually do end to end before the link cuts off?

Priya Raghavan14d ago

Naive question but if the agent compresses months of work, what specifically does an Incyte scientist do on day one with it? Click run and go to lunch?

Tomás Beltrán14d ago

Tagline rewrite, no charge: 'Kosmos: the lab partner that doesn't sleep, doesn't quit, and doesn't ask for authorship.' You can Venmo me.

fenwick14d ago

An autonomous agent generating hypotheses on real pharma pipelines is either the most exciting or the most terrifying thing I read this week. Possibly both.

Lior Banai14d ago

Every drug discovery AI launch shows a beautiful workflow diagram and zero failed assays. Show me the runs where Kosmos confidently proposed nonsense, then I'll believe.

Amara Okeke14d ago

The truncated tweet is the most powerful part of the launch. Half the replies are going to be people guessing what comes after 'into'.